Abstract

Previous studies suggested that XPO1 mutations participate in several steps of oncogenesis among multiple cancer types, and XPO1-mutant non-small-cell lung cancer (NSCLC) were associated with poorer survival contrast to their counterparts [2]. [...]finding novel strategies is urgently needed to improve the prognosis for XPO1-mutant NSCLC patients. [...]we further divided our patients into pure XPO1-mutant, wild type and XPO1-STK11/KEAP1 mutant groups. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.

Details

Title
XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
Author
Li, Xuanzong  VIAFID ORCID Logo  ; Zou, Bing; Wang, Shijiang; Wang, Linlin; Yu, Jinming
Pages
1-3
Section
Letter to the Editor
Publication year
2021
Publication date
2021
Publisher
BioMed Central
e-ISSN
14795876
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s12967-021-03098-5
ProQuest document ID
2583138767
Copyright
© 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.